Macular degeneration treatment depends on which type you have. Dry AMD, which accounts for about 80% to 90% of cases, has limited but growing treatment options focused on slowing progression. Wet AMD is treated with regular eye injections that can stabilize or even improve vision. Both types benefit from nutritional support, lifestyle changes, and vision rehabilitation tools.
Dry AMD: Slowing the Progression
For most people with dry age-related macular degeneration, the primary treatment strategy is nutritional supplementation. The AREDS2 formula, developed through a major clinical trial funded by the National Eye Institute, is a specific combination of vitamins and minerals shown to reduce the risk of progressing to advanced AMD. The formula contains 500 mg of vitamin C, 400 IU of vitamin E, 80 mg of zinc, 2 mg of copper, 10 mg of lutein, and 2 mg of zeaxanthin. These supplements are available over the counter and are most beneficial for people with intermediate dry AMD or advanced AMD in one eye.
The supplements don’t restore lost vision. They reduce the odds that moderate disease will advance to the severe stage where significant vision loss occurs.
Treatment for Geographic Atrophy
Geographic atrophy is the advanced form of dry AMD, where patches of cells in the macula permanently die off. Until recently, there was no treatment for this stage. In 2023, the FDA approved pegcetacoplan, the first drug specifically for geographic atrophy. It works by blocking part of the complement system, an immune pathway that contributes to the progressive cell death in the macula. The drug is delivered by injection into the eye every 30 to 60 days. A second complement-targeting drug, avacincaptad pegol, was also approved for the same condition. Neither drug reverses existing damage, but both slow the rate at which the atrophy spreads.
Wet AMD: Anti-VEGF Injections
Wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, rapidly damaging central vision. The standard treatment uses medications that block a protein called VEGF, which drives that abnormal vessel growth. Four drugs are approved for this purpose: aflibercept (Eylea), ranibizumab (Lucentis), brolucizumab (Beovu), and faricimab (Vabysmo). A fifth drug, bevacizumab (Avastin), is frequently used off-label at lower cost, though it’s technically approved only for cancer treatment.
These medications are injected directly into the eye. The procedure sounds alarming, but the eye is numbed beforehand and the injection itself takes seconds. Most people report feeling pressure rather than sharp pain.
How Often You’ll Need Injections
Treatment typically starts with three consecutive monthly injections, called loading doses, to get the disease under control. After that, the schedule depends on the approach your eye doctor uses. The most common strategy today is called “treat and extend.” At every visit you receive an injection, but if your retina looks stable on imaging, the interval between appointments gets pushed out by two to four weeks at a time, up to a maximum of 12 to 16 weeks depending on the medication. If signs of disease activity return, the interval gets shortened again.
An older approach called “as needed” (PRN) requires monthly monitoring visits but only gives injections when the disease flares. This means fewer injections but more office visits. Fixed dosing, where injections happen on a set monthly or bimonthly schedule regardless of disease activity, is less common now because of the treatment burden.
Most people with wet AMD need ongoing treatment for years, sometimes indefinitely. The good news is that anti-VEGF therapy stabilizes vision in the vast majority of patients, and many experience measurable improvement in the first year.
Photodynamic Therapy
Before anti-VEGF injections became available, photodynamic therapy (PDT) was a primary treatment for wet AMD. It involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser aimed at the abnormal blood vessels. PDT is no longer a first-line treatment for most wet AMD cases, but it remains useful for specific subtypes. These include polypoidal choroidal vasculopathy (a variant more common in people of Asian descent) and pachychoroid neovasculopathy, both of which can respond better to PDT than to injections alone. Current guidelines typically recommend combining PDT with anti-VEGF therapy rather than using it on its own.
Diet and Lifestyle Changes
Smoking is the single most modifiable risk factor for macular degeneration. Research in the British Journal of Ophthalmology found that current smokers had the highest odds of developing both forms of advanced AMD. People who quit saw their risk gradually decline, and those who had been smoke-free for more than 20 years had risk levels comparable to people who never smoked. If you currently smoke and have early AMD, quitting is one of the most impactful things you can do.
Diet also plays a role. Observational studies consistently show that people who eat more omega-3 fatty acids from fish are less likely to develop AMD. A study within the original AREDS trial found that participants with the highest omega-3 intake were about 30% less likely to progress to advanced disease compared to those with the lowest intake. However, randomized trials of omega-3 supplements have not confirmed that taking fish oil pills specifically prevents or slows AMD. The current evidence favors getting omega-3s through food, particularly fatty fish like salmon, sardines, and mackerel, rather than relying on supplements for this purpose. Leafy greens like spinach and kale are rich in lutein and zeaxanthin, the same pigments included in the AREDS2 formula, and are a cornerstone of an eye-healthy diet.
Monitoring Your Vision at Home
If you have dry AMD, catching a conversion to wet AMD early can make a significant difference in outcomes. The Amsler grid is a simple tool for daily self-monitoring. It’s a square grid with a dot in the center, and using it takes about 30 seconds:
- Wear your reading glasses and hold the grid 12 to 15 inches from your face in good light.
- Cover one eye.
- Focus on the center dot and notice whether any lines in your peripheral vision look wavy, blurry, dark, or blank.
- Repeat with the other eye.
If any area of the grid suddenly appears distorted, darker, or missing, contact your eye doctor right away. These changes can signal new fluid or bleeding under the retina, and prompt treatment within the first days to weeks gives the best chance of preserving vision.
The Implantable Miniature Telescope
For people with end-stage AMD who have already lost substantial central vision, an implantable miniature telescope is an FDA-approved surgical option. The tiny telescope is placed inside one eye during cataract surgery and magnifies images onto a larger area of the retina, working around the damaged macula. Eligibility is narrow: you must be 75 or older, have best-corrected vision between 20/160 and 20/800 in both eyes due to AMD, and have adequate peripheral vision in the non-surgical eye. The process includes pre-surgery training sessions with low vision specialists and continued rehabilitation afterward to learn how to use the device effectively.
Living With Vision Loss
Even with treatment, some degree of central vision loss is common in advanced AMD. Vision rehabilitation focuses on making the most of your remaining sight. Optical magnifiers, both handheld and mounted on glasses, enlarge text and objects. Video magnifiers combine a camera with a screen, letting you adjust contrast and zoom on printed material, photos, or small objects. Improving lighting throughout your home makes a practical difference: gooseneck lamps aimed directly at tasks, higher-wattage bulbs, and pocket flashlights for reading menus in dim restaurants.
Small environmental changes also help. Using high-contrast color combinations, like white plates on a dark tablecloth, makes daily tasks easier. Bold felt-tip markers are simpler to read than ballpoint pens. Large-print books, phones with oversized numbers, and audio-enabled devices for measuring blood pressure or blood sugar all reduce the impact of central vision loss on daily independence. A low vision specialist can evaluate your specific needs and recommend a tailored combination of tools and techniques.